IMMUNOPRECISE ANTIBODIES (TSXV: IPA) Q2 FY21 Revenue Rises 50% YoY

1 min read | December 21, 2020 11:43 AM EST | By Team Kalkine Media

Google News:

Recent News

Why Did WSP Global (TSX:WSP) Gain on UK Execution Shift in TSX 60?

Why Did Aecon Group (TSX:ARE) Gain on Churchill MOU in TSX Index?

Why Did Endeavour Silver (TSX:EDR) Gain on Terronera Drill Results in...

Why Did Maple Leaf Foods (TSX:MFI) Stock Dip After TSX Index Restructu...

Make Kalkine Media
My Trusted Source

The biotech firm reported revenue of C$ 4.8 million in the second quarter of FY21 (ending October 31, 2020), a surge of 50 per cent from C$ 3.2 million in Q2 FY20.
The healthcare company posted an adjusted EBITDA of nearly C$ 0.8 million for the quarter ending October 31, 2020.
The company recorded a current cash balance of C$ 16.8 million as of October 31, 2020, versus C$ 2.6 million a year ago.
IMMUNOPRECISE is actively investing in research and development (R&D) programs targeted at launching innovative services through both internal developments as well as through collaborations.

The company invested C$ 1.35 million in research and received C$ 2.154 million via grant income and subsidies by October 2020.

IPA stocks have been placed on TMX’s Rising Stars, Top Price Performers, and Top Healthcare companies, guided by its last month's stock performance. The biotech firm stock has rocketed over 68 per cent in just one month. Its scrips are currently trading at C$ 14.07 per unit. The stock has a price-to-book ratio of 11.824 and a present debt-to-equity (D/E) ratio of 0.25, as per the TMX data.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.